Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 3Neoplasms 2Leukemia 2Subcutaneous panniculitis-like T-cell lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Graft vs Host Disease 1

Interventions

Vincristine 3Prednisone 3Doxorubicin 3Cyclophosphamide 3pembrolizumab 2Vorinostat 2Etoposide 2Bortezomib 2siplizumab 1prednylidene 1pirarubicin 1liposomal doxorubicin 1etoposide phosphate 1Salvia hispanica seed extract 1Rituximab 1Methotrexate 1Ifosfamide 1Everolimus 1Cholecalciferol 1Brentuximab Vedotin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Subcutaneous panniculitis-like T-cell lymphoma × siplizumab × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡